Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$100.95 USD

100.95
866,060

-0.01 (-0.01%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $100.94 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 245)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hologic's Focal Therapeutics Buyout to Boost Breast Health Arm

by Zacks Equity Research

Hologic (HOLX) progresses with initiatives to boost the Breast Health unit. The recent buyout is likely to widen portfolio and fortify Hologic's position in the breast conserving surgery market.

    Zacks Equity Research

    Here's Why You Should Add Edwards Lifesciences Right Away

    by Zacks Equity Research

    We are upbeat about the continued strength in Edwards Lifesciences' (EW) THVT business.

      Zacks Equity Research

      Will LabCorp's (LH) Food Solution Divestment Upset Sales?

      by Zacks Equity Research

      LabCorp's (LH) lackluster outlook for 2018 includes the earlier-announced divestment of its Food Solutions business.

        Zacks Equity Research

        Neogen (NEOG) Earnings Beat, Revenues Lag Estimates in Q1

        by Zacks Equity Research

        Accretive integrations and an expanding international footprint drive Neogen's (NEOG) earnings in Q1.

          Zacks Equity Research

          Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?

          by Zacks Equity Research

          Style Box ETF report for FYC

            Zacks Equity Research

            Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?

            by Zacks Equity Research

            Is (AMED) Outperforming Other Medical Stocks This Year?

              Zacks Equity Research

              Here's Why You Should Invest in Walgreens Boots Stock Now

              by Zacks Equity Research

              Walgreens Boots (WBA) gains from tie-ups. The company's alliance with Express Scripts encourages.

                Zacks Equity Research

                Boston Scientific's FDA Nod for Eluvia Stent Expands PI Suite

                by Zacks Equity Research

                Boston Scientific's (BSX) PMA approval for Eluvia Drug-Eluting Vascular Stent System will help boost the top line at the PI business.

                  Zacks Equity Research

                  Medtronic to Buy Mazor Robotics for Robotic Spine Surgery

                  by Zacks Equity Research

                  The consolidation will combine Medtronic's (MDT) spine implants, navigation and intra-operative imaging technology with Mazor Robotics' robotic-assisted surgery (RAS) systems.

                    Zacks Equity Research

                    Cardiovascular Systems Stealth 360 Peripheral OAS Goes Global

                    by Zacks Equity Research

                    Following the recent extension of its partnership with OrbusNeich, Cardiovascular Systems' (CSII) Stealth 360 Peripheral OAS is put to first commercial use in Hong Kong.

                      Zacks Equity Research

                      Insulet Advances on Omnipod Reimbursement Update, Runs Risks

                      by Zacks Equity Research

                      Insulet (PODD) commences 2018 with favorable reimbursement updates. The company attains several landmarks regarding Omnipod's market reach.

                        Zacks Equity Research

                        Here's Why You Should Hold on to Align Technology (ALGN) Now

                        by Zacks Equity Research

                        Continued strength in Align Technology's (ALGN) Invisalign volumes impresses. Overdependence on Invisalign Technology system is a concern.

                          Zacks Equity Research

                          Zacks.com highlights: Insperity, Amedisys, Comfort Systems, Genesco and Forward Air

                          by Zacks Equity Research

                          Zacks.com highlights: Insperity, Amedisys, Comfort Systems, Genesco and Forward Air

                            Zacks Equity Research

                            ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio

                            by Zacks Equity Research

                            ResMed's (RMD) recent product launches will strengthen its position in the high-potential sleep-disordered breathing market.

                              Zacks Equity Research

                              QIAGEN (QGEN) Partners DiaSorin to Extend QuantFERON Offers

                              by Zacks Equity Research

                              Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.

                                Zacks Equity Research

                                Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                                by Zacks Equity Research

                                Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.

                                  Kevin Matras headshot

                                  Winning Stock Picks from the Top 5 Industries with the Biggest Job Growth

                                  by Kevin Matras

                                  Kevin Matras goes over how to find winning stock-picking ideas in the government's 'boring' economic reports. Highlighted stocks include NSP, AMED, FIX, GEN and FWRD.

                                    Zacks Equity Research

                                    QIAGEN Collaborates With NeuMoDx, Expands NGS Portfolio

                                    by Zacks Equity Research

                                    QIAGEN (QGEN) forges ahead with deals to strengthen the NGS Platform.

                                      Zacks Equity Research

                                      Omnicell Continues to Pursue Buyouts, Costs on the Rise

                                      by Zacks Equity Research

                                      Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.

                                        Zacks Equity Research

                                        Cardiovascular Systems Portfolio Strong, Competition Rife

                                        by Zacks Equity Research

                                        Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.

                                          Zacks Equity Research

                                          Here's Why You Should Invest in Penumbra (PEN) Stock Now

                                          by Zacks Equity Research

                                          The market is quite upbeat about Penumbra's (PEN) recently-closed buyout of a controlling stake in MVI Health, aimed at capturing the great potential of virtual reality application.

                                            Zacks Equity Research

                                            Here's Why You Should Retain IDEXX (IDXX) in Your Portfolio

                                            by Zacks Equity Research

                                            IDEXX (IDXX) continues to see strong organic growth. Adverse currency movement is a concern.

                                              Zacks Equity Research

                                              Here's Why You Should Retain QIAGEN (QGEN) in Your Portfolio

                                              by Zacks Equity Research

                                              A tough competitive landscape and strong reliance on relationships with collaborative partners is a major deterrent to QIAGEN (QGEN). The company's increased focus on the NGS portfolio is a positive.

                                                Zacks Equity Research

                                                Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?

                                                by Zacks Equity Research

                                                Genomic Health (GHDX) sees increasing private coverage for the Oncotype DX GPS test within the prostate cancer space.

                                                  Sapna Bagaria headshot

                                                  4 Stocks to Bet on the Burgeoning Home Healthcare Industry

                                                  by Sapna Bagaria

                                                  Growing senior population, increasing chronic illness, high cost of treatment at inpatient settings and preference by patients drives demand for home health care.